Aggressive Claims That Still Pass: The Substantiation Line in Supplement Ads

what does 'competent and reliable scientific evidence' actually mean?

'Competent and reliable scientific evidence' is the FTC's own test for whether a health claim can run, and the agency did not soften it in the 2022 Health Products Compliance Guidance. The Guidance defines it as research 'conducted and evaluated in an objective manner by experts in the relevant disease, condition, or function,' generally accepted in the profession as accurate and reliable. That single sentence decides more supplement claim substantiation FTC disputes than every disclaimer on a landing page combined.

The Guidance goes further than definition alone. It requires the research be sufficient in both quality and quantity when weighed against the entire body of relevant evidence, so a single glowing abstract from a pay-to-play journal does not satisfy the standard even when the study itself is well designed. One favorable data point, cited alone, is evidence of cherry-picking, not proof.

Randomized controlled human trials are the floor, not the ceiling, for this category. The 2022 Guidance states plainly that RCTs 'are the most reliable form of evidence,' and it excludes animal or in vitro studies from substantiating a health claim on their own. An advertiser holding only a rodent study on the active ingredient has a mechanism, not proof.

which claim structures survive both ad review and an FTC look?

Claim structures survive both an FTC review and ad-platform review when they tie a specific, cited outcome to a specific, disclosed population, not when they promise a universal result to everyone. The FTC's evidence test and each platform's ad-review policy target the same shape of statement, the dramatic and unqualified promise, so an architecture built to satisfy one usually satisfies the other. Platforms add a second filter the FTC does not: automated screening before the ad ever reaches a buyer.

Meta's ad review, per its own Advertising Standards, checks the ad's images, video, text, targeting and the landing page it points to, not the creative alone. Google Ads treats an 'improbable result... as the expected outcome' as an Unreliable Claims violation under its Misrepresentation policy, and TikTok's Weight Management policy bars any suggestion that a product alone, without diet or exercise, produces results. All three converge on the same forbidden shape: a specific number, no qualifier, no disclosed population.

None of the three platforms publishes a numeric spend threshold that earns lighter review, and none should be assumed to grant one. Meta's review 'relies primarily on automated tools' applied to every ad regardless of budget, and an ad can be re-reviewed after it already went live. Treat the thousandth dollar of spend as reviewed at the same bar as the first.

where is the line between structure-function and disease claims?

The line runs between a normal structure or function of the body and a named, diagnosable disease, and the FTC and FDA read it the same way even though they enforce it under different statutes. A claim that a mineral 'supports bone density' describes structure and function; a claim that it 'prevents osteoporosis' names a disease, because osteoporosis is a diagnosed medical condition rather than a description of ordinary physiology.

The distinction gets litigated one word at a time. The structure/function line for supplement ads runs through verbs almost as much as nouns — 'supports,' 'maintains' and 'promotes' read differently than 'treats,' 'reverses' or 'cures.' Meta's Health and Wellness policy draws an identical line: it bars claims to cure, heal or eliminate conditions like diabetes or cancer, including claims attributed to a health professional, while still allowing symptom-management language.

can you cite studies you didn't run on your own product?

Yes, but only when the cited research matches your product closely enough that the FTC would treat it as the same intervention: comparable active ingredient, comparable dose, comparable delivery form and a population similar to your buyer. The Guidance's 'entire body of relevant evidence' standard means a study on a different dose of the same compound, or the compound delivered as an injectable when you sell a capsule, actively damages a claim instead of propping it up.

This is where most VSL claim libraries actually originate, not from a company's own trial but from a citation chain built to make third-party research look product-specific, and the pattern behind how nutra VSLs build authority claims shows how consistently that chain gets stretched past what the underlying study supports. A citation that is real, peer-reviewed and irrelevant to your formulation is not weaker than no citation at all — it can be worse, since it signals the advertiser knew better research existed and chose not to match it.

do disclaimers actually reduce liability or just decorate the page?

Disclaimers mostly decorate the page rather than reduce liability, because a bare disclaimer does not cure a deceptive impression, and the FTC has said so in nearly identical language across three separate documents. The 2022 Guidance states that 'results not typical' doesn't cure deception; the 2023 Endorsement Guides revision at 16 CFR 255.2(e) lists the same phrase, plus its cousin about testimonials representing 'a few people,' as insufficient; and the January 2014 Gut Check guide told weight-loss advertisers the identical thing eleven years earlier. Three publications repeating the same rejection is not an oversight the agency forgot to update.

What actually functions as a defense is a substitute disclosure, not a warning label: the median result a typical user can expect, stated clearly enough that a consumer notices it before believing the dramatic number above it. The Endorsement Guides require the median rather than the mean specifically because outlier results distort an average upward, so an advertiser who discloses an average instead of a median may satisfy the letter of 'disclosure' while still misleading. This is the detail that separates a defensible fake testimonial FTC penalty case from an indefensible one — not whether a disclaimer exists, but which statistic it discloses.

how do the biggest compliant advertisers frame dramatic results?

The biggest compliant advertisers frame dramatic results as what a cited study measured, not as what the product promises, and they place a real, disclosed median next to it. The architecture reads like this: cite the trial, state its measured outcome in the trial's own terms, then separately and conspicuously disclose the results typical buyers actually get. Two numbers, two sentences, never merged into one implied promise.

This pattern shows up hardest in weight-loss and metabolic categories, where the FTC's substantiation rules for GLP-1-era claims sit against a backdrop of drugs with genuine randomized trial data, raising the bar for anything sold as an alternative or a complement. FDA's warning-letter volume against research-peptide and telehealth sellers of semaglutide and tirzepatide analogs runs to 139 letters touching semaglutide and 108 touching tirzepatide across 2024 through mid-2026, and the agency's stated theory is that intended use controls over research-only labeling — a lesson that applies just as directly to a supplement claiming a GLP-1-adjacent mechanism.

The seven per-se-false weight-loss claims the FTC listed in its 2014 Gut Check guide remain the brightest line in the category, and compliant advertisers structure copy to avoid all seven rather than softening one and leaving the rest intact. No diet-or-exercise-free claim, no permanent-after-stopping claim, no all-users claim and no topical-absorption claim survives contact with that list, regardless of how carefully the disclaimer around it is worded.

what should a pre-launch claims audit check before the first dollar of spend?

A pre-launch audit checks whether every claim in the funnel has a study behind it that matches the product, not whether a study exists somewhere in the literature. Build the checklist before creative goes into ad review, because platform rejection and supplement claim substantiation FTC exposure are graded against the same underlying evidence gap.

Keep the studies, the disclosure drafts and the internal sign-off in one place: the substantiation file every claim needs is the artifact that turns a defensible claim into a documented one if the FTC or a platform ever asks. An audit that lives only in someone's head is not an audit; it is a claim about having done an audit, which is exactly the kind of unsubstantiated assertion this page is about.

• Each health claim traced to a specific study, with ingredient, dose and delivery form matching the product being sold, not a related formulation
• RCT-level evidence required for anything read as a disease claim; observational or animal data flagged as insufficient on its own
• Every testimonial checked against the typical result it implies, with a median — not average — disclosure drafted before launch, not added after a complaint
• Landing page audited alongside the ad creative, since Meta, Google and TikTok all review the destination page as part of the ad
• Negative-option billing terms — price, frequency, cancellation mechanism — disclosed before payment info is collected, per ROSCA's three-part test
• Ownership and control mapped, since the FTC's control-or-participation standard reaches individual officers and agencies, not only the corporate entity

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

When the topic touches health claims, platform policy, or GLP-1 market research, validate the observable campaign signals against primary references such as Meta advertising standards, FTC health claims guidance, and Google helpful content guidance. Daily Intel adds the proprietary direct-response layer by mapping how those rules show up in active VSLs, Meta creatives, funnels, transcripts, UTMs, and checkout paths.

For deeper evaluation, continue through Daily Intel compliance and legal disclaimer, How to Identify a Competitor's Tracker From the URL, Meta Ad Library API Limits: The Fields It Won't Return, Circumventing Systems Ban: Why Meta Disabled Your Account, Before and After Photos in Meta Ads: 2026 Policy Shift, and What is a VSL?. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.